\babel@toc {english}{}
\contentsline {part}{I\hspace {1em}Notes}{2}{part.1}%
\contentsline {chapter}{\numberline {1}Introduction}{3}{chapter.1}%
\contentsline {section}{\numberline {1.1}Genetics vs Genomics}{3}{section.1.1}%
\contentsline {subsection}{\numberline {1.1.1}Genetics}{3}{subsection.1.1.1}%
\contentsline {subsection}{\numberline {1.1.2}Genomics}{3}{subsection.1.1.2}%
\contentsline {subsection}{\numberline {1.1.3}Differences}{3}{subsection.1.1.3}%
\contentsline {subsection}{\numberline {1.1.4}Role of computational biology}{3}{subsection.1.1.4}%
\contentsline {section}{\numberline {1.2}Human Genomics - the Basis}{4}{section.1.2}%
\contentsline {subsection}{\numberline {1.2.1}Genetic Make-Up}{4}{subsection.1.2.1}%
\contentsline {subsubsection}{\numberline {1.2.1.1}Single nucleotide polymorphisms}{4}{subsubsection.1.2.1.1}%
\contentsline {subsubsection}{\numberline {1.2.1.2}Copy number variants}{4}{subsubsection.1.2.1.2}%
\contentsline {subsection}{\numberline {1.2.2}Inherited variants' relevance}{4}{subsection.1.2.2}%
\contentsline {paragraph}{\numberline {1.2.2.0.1}Penetrance}{4}{paragraph.1.2.2.0.1}%
\contentsline {paragraph}{\numberline {1.2.2.0.2}Allele frequency}{5}{paragraph.1.2.2.0.2}%
\contentsline {subsection}{\numberline {1.2.3}Differences in Genetic Make-Up, an example}{5}{subsection.1.2.3}%
\contentsline {subsection}{\numberline {1.2.4}Acquired DNA aberrations}{5}{subsection.1.2.4}%
\contentsline {subsubsection}{\numberline {1.2.4.1}Types of acquired DNA aberrations}{5}{subsubsection.1.2.4.1}%
\contentsline {paragraph}{\numberline {1.2.4.1.1}Translocation}{5}{paragraph.1.2.4.1.1}%
\contentsline {paragraph}{\numberline {1.2.4.1.2}Inversion}{5}{paragraph.1.2.4.1.2}%
\contentsline {paragraph}{\numberline {1.2.4.1.3}Copy number changes}{6}{paragraph.1.2.4.1.3}%
\contentsline {paragraph}{\numberline {1.2.4.1.4}Chromoplexy}{6}{paragraph.1.2.4.1.4}%
\contentsline {paragraph}{\numberline {1.2.4.1.5}Chromothripsis}{6}{paragraph.1.2.4.1.5}%
\contentsline {paragraph}{\numberline {1.2.4.1.6}Kataegis}{6}{paragraph.1.2.4.1.6}%
\contentsline {section}{\numberline {1.3}Experimental techniques to detect variants/aberrations}{6}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Cariotyping}{6}{subsection.1.3.1}%
\contentsline {section}{\numberline {1.4}Sequence capture for cancer genomics}{6}{section.1.4}%
\contentsline {subsection}{\numberline {1.4.1}Single End (SE) and Paired End (PE) reads}{7}{subsection.1.4.1}%
\contentsline {chapter}{\numberline {2}Coverage}{8}{chapter.2}%
\contentsline {section}{\numberline {2.1}Local Coverage and Allelic Fraction}{8}{section.2.1}%
\contentsline {paragraph}{\numberline {2.1.0.0.1}Local coverage (cov)}{8}{paragraph.2.1.0.0.1}%
\contentsline {paragraph}{\numberline {2.1.0.0.2}Allelic fraction (AF)}{8}{paragraph.2.1.0.0.2}%
\contentsline {subsection}{\numberline {2.1.1}Mapped reads}{8}{subsection.2.1.1}%
\contentsline {paragraph}{\numberline {2.1.1.0.1}Sequence coverage:}{9}{paragraph.2.1.1.0.1}%
\contentsline {paragraph}{\numberline {2.1.1.0.2}Physical coverage:}{9}{paragraph.2.1.1.0.2}%
\contentsline {section}{\numberline {2.2}When to increase the intended coverage of a NGS assay}{9}{section.2.2}%
\contentsline {section}{\numberline {2.3}Interpreting Pair Orientations}{10}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}Inversion}{10}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}Tandem duplication}{11}{subsection.2.3.2}%
\contentsline {subsection}{\numberline {2.3.3}Inverted duplication}{11}{subsection.2.3.3}%
\contentsline {section}{\numberline {2.4}Summary}{11}{section.2.4}%
\contentsline {chapter}{\numberline {3}Genetic Fingerprinting}{12}{chapter.3}%
\contentsline {subsection}{\numberline {3.0.1}Variants used for genetic testing}{12}{subsection.3.0.1}%
\contentsline {section}{\numberline {3.1}SNPs features}{12}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}Hardy-Weinberg equilibrium and Minor Allele frequency}{12}{subsection.3.1.1}%
\contentsline {subsection}{\numberline {3.1.2}Minor Allele Frequency}{13}{subsection.3.1.2}%
\contentsline {subsection}{\numberline {3.1.3}Haplotype Blocks}{13}{subsection.3.1.3}%
\contentsline {subsection}{\numberline {3.1.4}Other SNPs features}{14}{subsection.3.1.4}%
\contentsline {subsection}{\numberline {3.1.5}Number of SNPs to select}{15}{subsection.3.1.5}%
\contentsline {subsubsection}{\numberline {3.1.5.1}Experimental mismatches : Genotype call error rate}{15}{subsubsection.3.1.5.1}%
\contentsline {subsection}{\numberline {3.1.6}Some questions}{19}{subsection.3.1.6}%
\contentsline {subsection}{\numberline {3.1.7}Further considerations}{19}{subsection.3.1.7}%
\contentsline {section}{\numberline {3.2}Building a SNP-based genetic test}{20}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}Implementation of a probabilistic test}{20}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}Example 1: Cell line passages}{22}{subsection.3.2.2}%
\contentsline {subsection}{\numberline {3.2.3}Individual's Relatedness (genotype-distance)}{23}{subsection.3.2.3}%
\contentsline {subsection}{\numberline {3.2.4}Example 3: Cancer supscettibility test}{23}{subsection.3.2.4}%
\contentsline {subsection}{\numberline {3.2.5}Genetic structure of the human population}{24}{subsection.3.2.5}%
\contentsline {subsubsection}{\numberline {3.2.5.1}Example paper: 'Genes mirror geography within Europe'}{24}{subsubsection.3.2.5.1}%
\contentsline {subsubsection}{\numberline {3.2.5.2}Summary and notes}{25}{subsubsection.3.2.5.2}%
\contentsline {chapter}{\numberline {4}IGV (Integrative Genomics Viewer)}{27}{chapter.4}%
\contentsline {section}{\numberline {4.1}Main characteristics}{27}{section.4.1}%
\contentsline {subsection}{\numberline {4.1.1}Igvtools}{31}{subsection.4.1.1}%
\contentsline {subsection}{\numberline {4.1.2}Session Files}{31}{subsection.4.1.2}%
\contentsline {section}{\numberline {4.2}Some of the main utilizations}{32}{section.4.2}%
\contentsline {subsection}{\numberline {4.2.1}RNA-seq alignments}{32}{subsection.4.2.1}%
\contentsline {subsection}{\numberline {4.2.2}Study of variants}{32}{subsection.4.2.2}%
\contentsline {section}{\numberline {4.3}Exercise}{33}{section.4.3}%
\contentsline {subsection}{\numberline {4.3.1}Task B}{34}{subsection.4.3.1}%
\contentsline {chapter}{\numberline {5}Tumor Evolution Studies via NGS data}{37}{chapter.5}%
\contentsline {section}{\numberline {5.1}Tumor evolution}{37}{section.5.1}%
\contentsline {section}{\numberline {5.2}From sketches to sequencing data evolution information}{40}{section.5.2}%
\contentsline {subsection}{\numberline {5.2.1}Tumor evolution and heterogeneity}{40}{subsection.5.2.1}%
\contentsline {subsubsection}{\numberline {5.2.1.1}Admixture}{40}{subsubsection.5.2.1.1}%
\contentsline {subsection}{\numberline {5.2.2}Useful feature from NGS data}{40}{subsection.5.2.2}%
\contentsline {subsection}{\numberline {5.2.3}Allelic Fraction (AF) properties}{41}{subsection.5.2.3}%
\contentsline {section}{\numberline {5.3}Coverage and AF properties}{41}{section.5.3}%
\contentsline {section}{\numberline {5.4}Computing Beta}{43}{section.5.4}%
\contentsline {section}{\numberline {5.5}Global vs Local Estimates of admixture}{43}{section.5.5}%
\contentsline {subsubsection}{\numberline {5.5.0.1}Estimate of DNA admixture (1-Purity)}{43}{subsubsection.5.5.0.1}%
\contentsline {section}{\numberline {5.6}A challenging case (PR-2741}{44}{section.5.6}%
\contentsline {chapter}{\numberline {6}Tumor evolution studies (continued)}{45}{chapter.6}%
\contentsline {section}{\numberline {6.1}Recalls from the previous lecture}{45}{section.6.1}%
\contentsline {section}{\numberline {6.2}Ploidy and purity correction on $\log _2(\frac {T}{N})$ data}{50}{section.6.2}%
\contentsline {chapter}{\numberline {7}Tumor evolution studies via NGS data: SNVs-based methods}{62}{chapter.7}%
\contentsline {section}{\numberline {7.1}Rationale of somatic point mutation based assays}{62}{section.7.1}%
\contentsline {section}{\numberline {7.2}TPES (Tumor Purity Estimation)}{63}{section.7.2}%
\contentsline {section}{\numberline {7.3}How many SNVs are needed to assess tumor purity?}{63}{section.7.3}%
\contentsline {section}{\numberline {7.4}Comparison between purity callers}{64}{section.7.4}%
\contentsline {section}{\numberline {7.5}Pros and Cons of SNVs-based tumor purity assessment}{64}{section.7.5}%
\contentsline {chapter}{\numberline {8}Liquid biopsies in oncology}{66}{chapter.8}%
\contentsline {section}{\numberline {8.1}Liquid vs Tissue biopsies}{66}{section.8.1}%
\contentsline {section}{\numberline {8.2}Issues in the interpretation of cfDNA data}{67}{section.8.2}%
\contentsline {subsection}{\numberline {8.2.1}Normalization on tumor content}{67}{subsection.8.2.1}%
\contentsline {subsection}{\numberline {8.2.2}Quantity of input material}{67}{subsection.8.2.2}%
\contentsline {section}{\numberline {8.3}SNV detection in liquid biopsies}{68}{section.8.3}%
\contentsline {section}{\numberline {8.4}Requirements depend on the application}{71}{section.8.4}%
\contentsline {section}{\numberline {8.5}Whole genome vs targeted sequencing}{71}{section.8.5}%
\contentsline {section}{\numberline {8.6}Take-home message}{72}{section.8.6}%
\contentsline {chapter}{\numberline {9}Epigenetic profiling of cell-free DNA}{73}{chapter.9}%
\contentsline {section}{\numberline {9.1}Introduction}{73}{section.9.1}%
\contentsline {section}{\numberline {9.2}DNA methylation}{73}{section.9.2}%
\contentsline {section}{\numberline {9.3}How is DNA methylation measured?}{74}{section.9.3}%
\contentsline {section}{\numberline {9.4}Tissue-specific vs disease-specific DNA markers}{75}{section.9.4}%
\contentsline {section}{\numberline {9.5}DNA methylation based liquid biopsy}{75}{section.9.5}%
\contentsline {subsection}{\numberline {9.5.1}Workflow}{76}{subsection.9.5.1}%
\contentsline {subsection}{\numberline {9.5.2}CCGA study}{76}{subsection.9.5.2}%
\contentsline {subsection}{\numberline {9.5.3}Deconvolution approaches}{77}{subsection.9.5.3}%
\contentsline {section}{\numberline {9.6}Targeted panel approaches for tumor content estimation}{77}{section.9.6}%
\contentsline {part}{II\hspace {1em}Papers}{79}{part.2}%
\contentsline {chapter}{\numberline {10}Role of non-coding sequence variants in cancer}{80}{chapter.10}%
\contentsline {section}{\numberline {10.1}Abstract}{80}{section.10.1}%
\contentsline {subsection}{\numberline {10.1.1}Introduction}{80}{subsection.10.1.1}%
\contentsline {section}{\numberline {10.2}Genomic sequence variants}{80}{section.10.2}%
\contentsline {section}{\numberline {10.3}Non-coding element annotation}{81}{section.10.3}%
\contentsline {subsection}{\numberline {10.3.1}Cis regulatory regions}{81}{subsection.10.3.1}%
\contentsline {subsection}{\numberline {10.3.2}Distal regulatory elements}{81}{subsection.10.3.2}%
\contentsline {subsection}{\numberline {10.3.3}RNA-seq}{81}{subsection.10.3.3}%
\contentsline {subsection}{\numberline {10.3.4}Transcribed pseudogenes}{81}{subsection.10.3.4}%
\contentsline {subsection}{\numberline {10.3.5}Evolutionary conservation}{82}{subsection.10.3.5}%
\contentsline {section}{\numberline {10.4}Roles for somatic variants in cancer}{82}{section.10.4}%
\contentsline {subsection}{\numberline {10.4.1}Gain of TF-binding sites}{82}{subsection.10.4.1}%
\contentsline {subsection}{\numberline {10.4.2}Fusion events due to genomic rearrangements}{82}{subsection.10.4.2}%
\contentsline {subsection}{\numberline {10.4.3}ncRNAs and their binding sites}{82}{subsection.10.4.3}%
\contentsline {subsection}{\numberline {10.4.4}Role of pseudogenes in modulating the expression of a parental gene}{83}{subsection.10.4.4}%
\contentsline {section}{\numberline {10.5}Roles for germline variants in cancer}{83}{section.10.5}%
\contentsline {subsection}{\numberline {10.5.1}Promoter mutations}{83}{subsection.10.5.1}%
\contentsline {subsection}{\numberline {10.5.2}SNPs in enhancers}{83}{subsection.10.5.2}%
\contentsline {subsection}{\numberline {10.5.3}Variants in introns}{83}{subsection.10.5.3}%
\contentsline {subsection}{\numberline {10.5.4}SNPs in ncRNA and their binding sites}{83}{subsection.10.5.4}%
\contentsline {subsection}{\numberline {10.5.5}Others}{83}{subsection.10.5.5}%
\contentsline {section}{\numberline {10.6}Interplay between germline and somatic variants}{83}{section.10.6}%
\contentsline {section}{\numberline {10.7}Computational methods for identifying variants}{84}{section.10.7}%
\contentsline {section}{\numberline {10.8}Experimental approaches for functional validation}{84}{section.10.8}%
\contentsline {chapter}{\numberline {11}Advances in understanding cancer genomics through second-generation sequencing}{86}{chapter.11}%
\contentsline {section}{\numberline {11.1}Abstract}{86}{section.11.1}%
\contentsline {subsection}{\numberline {11.1.1}Introduction}{86}{subsection.11.1.1}%
\contentsline {section}{\numberline {11.2}Cancer-specific consideration}{86}{section.11.2}%
\contentsline {subsection}{\numberline {11.2.1}Characteristics of cancer samples for genomic analysis}{87}{subsection.11.2.1}%
\contentsline {subsection}{\numberline {11.2.2}Structural variability of cancer genomes}{87}{subsection.11.2.2}%
\contentsline {section}{\numberline {11.3}Experimental approaches}{87}{section.11.3}%
\contentsline {subsection}{\numberline {11.3.1}Whole genome sequencing}{87}{subsection.11.3.1}%
\contentsline {subsection}{\numberline {11.3.2}Exome sequencing}{87}{subsection.11.3.2}%
\contentsline {subsection}{\numberline {11.3.3}Transcriptome sequencing}{88}{subsection.11.3.3}%
\contentsline {section}{\numberline {11.4}Detecting classes of genome alterations}{88}{section.11.4}%
\contentsline {subsection}{\numberline {11.4.1}Somatic nucleotide substitutions and small insertion and deletion mutations}{88}{subsection.11.4.1}%
\contentsline {subsection}{\numberline {11.4.2}Copy number}{88}{subsection.11.4.2}%
\contentsline {subsection}{\numberline {11.4.3}Chromosomal rearrangements}{88}{subsection.11.4.3}%
\contentsline {subsection}{\numberline {11.4.4}Microbe-discovery methods}{89}{subsection.11.4.4}%
\contentsline {section}{\numberline {11.5}Computational issues}{89}{section.11.5}%
\contentsline {subsection}{\numberline {11.5.1}Alignment and assembly}{89}{subsection.11.5.1}%
\contentsline {subsection}{\numberline {11.5.2}mutations detection}{89}{subsection.11.5.2}%
\contentsline {subsection}{\numberline {11.5.3}Validation of mutation and rearrangement calls}{89}{subsection.11.5.3}%
\contentsline {chapter}{\numberline {12}Integrative genomics viewer}{91}{chapter.12}%
\contentsline {section}{\numberline {12.1}Introduction}{91}{section.12.1}%
\contentsline {chapter}{\numberline {13}Tumour heterogeneity and resistance to cancer therapies}{92}{chapter.13}%
\contentsline {section}{\numberline {13.1}Abstract}{92}{section.13.1}%
\contentsline {subsection}{\numberline {13.1.1}Introduction}{92}{subsection.13.1.1}%
\contentsline {section}{\numberline {13.2}Causes of intratumoral heterogeneity}{92}{section.13.2}%
\contentsline {subsection}{\numberline {13.2.1}Genomic instability}{92}{subsection.13.2.1}%
\contentsline {subsection}{\numberline {13.2.2}The clonal evolution and selection hypothesis}{93}{subsection.13.2.2}%
\contentsline {section}{\numberline {13.3}The spectrum of tumour heterogeneity}{93}{section.13.3}%
\contentsline {subsection}{\numberline {13.3.1}Spatial heterogeneity}{93}{subsection.13.3.1}%
\contentsline {subsubsection}{\numberline {13.3.1.1}Heterogeneity at a single disease site}{93}{subsubsection.13.3.1.1}%
\contentsline {subsubsection}{\numberline {13.3.1.2}Comparison of spatially distinct disease sites}{93}{subsubsection.13.3.1.2}%
\contentsline {subsection}{\numberline {13.3.2}Temporal heterogeneity}{94}{subsection.13.3.2}%
\contentsline {subsubsection}{\numberline {13.3.2.1}Genomic complexity might increase with exposure to targeted therapies}{94}{subsubsection.13.3.2.1}%
\contentsline {subsubsection}{\numberline {13.3.2.2}Longitudinal sampling provides insight into temporal heterogeneity}{94}{subsubsection.13.3.2.2}%
\contentsline {subsubsection}{\numberline {13.3.2.3}Residual drug-tolerant cells can foster temporal heterogeneity}{94}{subsubsection.13.3.2.3}%
\contentsline {section}{\numberline {13.4}Noninvasive monitoring of heterogeneity}{95}{section.13.4}%
\contentsline {subsection}{\numberline {13.4.1}Analysis of ctDNA}{95}{subsection.13.4.1}%
\contentsline {section}{\numberline {13.5}Overcoming heterogeneity}{95}{section.13.5}%
\contentsline {chapter}{\numberline {14}Unravelling the clonal hierarchy of somatic genomic aberrations}{97}{chapter.14}%
\contentsline {section}{\numberline {14.1}Introduction}{97}{section.14.1}%
\contentsline {subsection}{\numberline {14.1.1}Abstract}{97}{subsection.14.1.1}%
\contentsline {subsection}{\numberline {14.1.2}Background}{97}{subsection.14.1.2}%
\contentsline {section}{\numberline {14.2}Results}{98}{section.14.2}%
\contentsline {subsection}{\numberline {14.2.1}Clonality assessment of aberrations from sequencing reads}{98}{subsection.14.2.1}%
\contentsline {subsection}{\numberline {14.2.2}Inferring the order of mutations in a tumour sample}{98}{subsection.14.2.2}%
\contentsline {subsection}{\numberline {14.2.3}In silico and in situ experimental validation}{99}{subsection.14.2.3}%
\contentsline {subsection}{\numberline {14.2.4}Comparative analysis reveals different mechanisms of tumour deregulation}{99}{subsection.14.2.4}%
\contentsline {subsection}{\numberline {14.2.5}Clonal hierarchy of genomic aberrations}{100}{subsection.14.2.5}%
\contentsline {section}{\numberline {14.3}Materials and methods}{100}{section.14.3}%
\contentsline {subsection}{\numberline {14.3.1}CLONET pipeline}{100}{subsection.14.3.1}%
\contentsline {subsection}{\numberline {14.3.2}CLONET on exome and targeted sequencing data}{100}{subsection.14.3.2}%
\contentsline {subsection}{\numberline {14.3.3}Expected distribution of the allelic fraction of a genomic segment}{100}{subsection.14.3.3}%
\contentsline {subsection}{\numberline {14.3.4}Estimated proportion of neutral reads for a genomic segment}{101}{subsection.14.3.4}%
\contentsline {subsection}{\numberline {14.3.5}From neutral to non-aberrant reads}{101}{subsection.14.3.5}%
\contentsline {subsection}{\numberline {14.3.6}From aberrant reads to aberrant cells}{101}{subsection.14.3.6}%
\contentsline {subsection}{\numberline {14.3.7}Uncertainty assessment and its propagation to clonality estimates}{102}{subsection.14.3.7}%
\contentsline {subsection}{\numberline {14.3.8}Clonality of bi-allelic deletion}{102}{subsection.14.3.8}%
\contentsline {chapter}{\numberline {15}TPES: timor purity estimation from SNVs}{103}{chapter.15}%
\contentsline {section}{\numberline {15.1}Abstract}{103}{section.15.1}%
\contentsline {subsection}{\numberline {15.1.1}Introduction}{103}{subsection.15.1.1}%
\contentsline {section}{\numberline {15.2}Materials and methods}{103}{section.15.2}%
\contentsline {chapter}{\numberline {16}SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines}{105}{chapter.16}%
\contentsline {section}{\numberline {16.1}Abstract}{105}{section.16.1}%
\contentsline {subsection}{\numberline {16.1.1}Introduction}{105}{subsection.16.1.1}%
\contentsline {section}{\numberline {16.2}Material and methods}{105}{section.16.2}%
\contentsline {subsection}{\numberline {16.2.1}Genotype distance}{105}{subsection.16.2.1}%
\contentsline {subsection}{\numberline {16.2.2}SNP panel selection procedure}{106}{subsection.16.2.2}%
\contentsline {subsection}{\numberline {16.2.3}SPIA probabilistic test on cell line genotype distance}{106}{subsection.16.2.3}%
